Natural History of Severe Ulcerative Colitis in a Community-Based Health Plan

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 9, 2008, Pages 999-1003

  Allison, James ^a,b   Herrinton, Lisa J ^a   Liu, Liyan ^a   Yu, Jenny ^a   Lowder, James ^c  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PDL BioPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COLON RESECTION; COMMUNITY CARE; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENTERITIS; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTCOME ASSESSMENT; RISK FACTOR; STEROID THERAPY; SURVIVAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COLECTOMY; COLITIS, ULCERATIVE; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; STEROIDS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 50649087272     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.05.022     Document Type: Article

References (13)

1. Moum B., Ekbom A., Vatn M.H., et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 32 (1997) 1005-1012
2. Kornbluth A., Lichtiger S., Present D., et al. Long-term results of oral cyclosporine in patients with severe ulcerative colitis: a double-blind, randomized multicenter trial. Gastroenterology 106 (1994) A714
3. Langholz E., Munkholm P., Davidsen M., et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107 (1994) 3-11
4. Selby W. The natural history of ulcerative colitis. Baillieres Clin Gastroenterol 11 (1997) 53-64
5. Hiwatashi N., Yao T., Watanabe H., et al. Long-term follow-up study of ulcerative colitis in Japan. J Gastroenterol 30 Suppl 8 (1995) 13-16
6. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
7. Loftus C.G., Egan L.J., and Sandborn W.J. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 33 (2004) 141-169
8. Kalbfleisch J.D., and Prentice R.L. Estimation of the average hazard ratio. Biometrika 68 (1981) 105-112
9. Turner D., Walsh C.M., Steinhart A.H., et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 5 (2007) 103-110
10. Petri H., and Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 10 (1991) 577-581
11. Henriksen M., Jahnsen J., Lygren I., et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 12 (2006) 543-550
12. Leijonmarck C.E., Persson B.G., and Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 31 (1990) 329-333
13. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260